Form 4 for AYTU AYTU BIOPHARMA, INC
Accepted 2023-06-20 00:00:00 ET · period of report 2023-04-25 · accession 0000912282-23-000135 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-20 | 2023-04-25 | AYTU | PYSZCZYMUKA GREG | Chief Commerical Off | M - OptEx | $0.00 | +833 | 9,935 | +9% | $0 |
| D | 2023-06-20 | 2023-04-25 | AYTU | PYSZCZYMUKA GREG | Chief Commerical Off | M - OptEx | $0.00 | -833 | 1,667 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-04-25 | M | A | 833 | $0.00 | 9,935 | D | — | — | (F1) Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023. |
| 2 | Derivative | Restricted Stock Units | 2023-04-25 | M | D | 833 | $0.00 | 1,667 | D | — · — to — | 833 Common Shares | (F1) Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023. (F2) Represents restricted stock units ("RSU"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting. |